Table 5.
Characteristics of patients with autopsy study available.
| Mold Infection Confirmed in Autopsy (n: 4) | Mold Infection Not Confirmed in Autopsy (n: 27) | |
|---|---|---|
| SARS-CoV-2 infection | 4/4 (100%) | 27/27 (100%) |
| Proven, probable or possible IPA | 4/4 (100%) | 3/27 (11.1%) |
| Proven or probable IPA | 4/4 (100%) | 2/27 (7.4%) |
| Aspergillus isolated in sputum | 1/4(25%) | 4/27 (14.8%) |
| Aspergillus isolated in tracheo-bronchial aspirate | 0/4 (0%) | 3/27 (11.1%) |
| Aspergillus isolated in BAL (all patients) | 0/4 (0%) | 1/27 (3.7%) |
| Aspergillus isolated in BAL (if available) | 0/2 (0%) | 1/4(25%) |
| Hyphae were observed in BAL | 0/4 (0%) | 1/27 (3.7%) |
| Positive GM in BAL (all patients) | 1/4(25%) | 1/27 (3.7%) |
| Positive GM in serum (all patients) | 0/4 (0%) | 0/27 (0%) |
| Type of pulmonary infiltrate | ||
| -No infiltrate | 0/4 (0%) | 0/27 (0%) |
| -Nodular or bilateral, ground-glass opacities | 1/4 (25%) | 23/27 (85.2%) |
| -Caveat | 0/4 (0%) | 0/27 (0%) |
| -Pulmonary embolism | 3/4 (75%) | 4/27 (14.8%) |
| -Pleural fluid | 2/4 (50%) | 11/27 (40.7%) |
IPA: invasive pulmonary aspergillosis. GM: galactomannan. BAL: bronchoalveolar lavage.